These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 12765126)

  • 41. Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1.
    Pérez-Alvarez L; Carmona R; Ocampo A; Asorey A; Miralles C; Pérez de Castro S; Pinilla M; Contreras G; Taboada JA; Nájera R
    J Med Virol; 2006 Feb; 78(2):141-7. PubMed ID: 16372284
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New-Fill on "hold" and open-label for T-20.
    Berger DS
    Posit Aware; 2002; 13(1):64-5. PubMed ID: 12216532
    [No Abstract]   [Full Text] [Related]  

  • 43. Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies.
    Negredo E; Bonjoch A; Paredes R; Puig J; Clotet B
    Clin Infect Dis; 2005 Sep; 41(6):901-5. PubMed ID: 16107993
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [On the path to "e-HAART"? Glimpse at salvage therapy].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():24-5. PubMed ID: 11373771
    [No Abstract]   [Full Text] [Related]  

  • 45. Use of darunavir and enfuvirtide in a pregnant woman.
    Sued O; Lattner J; Gun A; Patterson P; Abusamra L; Cesar C; Fink V; Krolewiecki A; Cahn P
    Int J STD AIDS; 2008 Dec; 19(12):866-7. PubMed ID: 19050223
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid.
    van Lelyveld SF; Nijhuis M; Baatz F; Wilting I; van den Bergh WM; Kurowski M; de Jong D; Hoepelman AI; Wensing AM
    Clin Infect Dis; 2010 Feb; 50(3):387-90. PubMed ID: 20047481
    [TBL] [Abstract][Full Text] [Related]  

  • 47. T-1249 development suspended.
    Huff B
    GMHC Treat Issues; 2003 Dec; 17(12):6. PubMed ID: 15011643
    [No Abstract]   [Full Text] [Related]  

  • 48. [Fusion proteins in HIV-AIDS treatment].
    Hennemann A
    Med Monatsschr Pharm; 2003 Sep; 26(9):300-2. PubMed ID: 14526613
    [No Abstract]   [Full Text] [Related]  

  • 49. T-20 small program, CD4 < 50, will enroll November 27 at 3:00 P.M.
    James JS
    AIDS Treat News; 2001 Oct; (373):3. PubMed ID: 11768880
    [No Abstract]   [Full Text] [Related]  

  • 50. New fixed-dose once-a-day starting regimens: interview with Cal Cohen, M.D. Interview by John S. James.
    Cohen C
    AIDS Treat News; 2004 Sep; (405):3-6. PubMed ID: 15595150
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor.
    Cervia JS; Smith MA
    Clin Infect Dis; 2003 Oct; 37(8):1102-6. PubMed ID: 14523775
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Enfuvirtide desensitisation: due to a failed case].
    López-de-Torre Querejazu A; Ibarra Barrueta O; Santos Ibañez A; Mayo Suárez J
    Farm Hosp; 2012; 36(2):112-3. PubMed ID: 22024011
    [No Abstract]   [Full Text] [Related]  

  • 53. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
    Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
    N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
    [TBL] [Abstract][Full Text] [Related]  

  • 54. "Switch" studies for people with lipodystrophy.
    Proj Inf Perspect; 2000 Aug; (30):9. PubMed ID: 12171017
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). T-1249 for T-20 salvage.
    Feinberg J
    AIDS Clin Care; 2003 Nov; 15(11):95-6. PubMed ID: 14682275
    [No Abstract]   [Full Text] [Related]  

  • 56. Subcutaneous injection survey: psychometric evaluation of a treatment satisfaction instrument associated with a novel HIV medication.
    Green J; Kleinman L; Ciesla G; Huang J; Wintfeld N; Revicki D
    HIV Clin Trials; 2002; 3(5):387-95. PubMed ID: 12407488
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nailing down another HIV target.
    Richman DD
    Nat Med; 1998 Nov; 4(11):1232-3. PubMed ID: 9809537
    [No Abstract]   [Full Text] [Related]  

  • 58. Anti-HIV agents. T-20 shows its potency.
    TreatmentUpdate; 2002 Aug; 14(6):5-6. PubMed ID: 12238452
    [No Abstract]   [Full Text] [Related]  

  • 59. Anti-HIV agents. Valproic acid and HIV eradication--many questions remain.
    TreatmentUpdate; 2005; 17(6):5-7. PubMed ID: 17228476
    [No Abstract]   [Full Text] [Related]  

  • 60. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. T-20 salvage results hold up at 48 weeks.
    Feinberg J
    AIDS Clin Care; 2003 Sep; 15(9):77-8. PubMed ID: 14666913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.